Posted by Michael Wonder on 19 Jan 2020
Is innovation causing accessibility, timing issues for private drug plans?
17 January 2020 - Pharmaceutical companies and private payers can interact in different ways to ensure the right drugs are getting to the right patients, according to Kathy Sotirakos, senior manager of market access and private insurance at Amgen.
Real world evidence will help inform better decision-making from a predictability and outcomes perspective, she said during a panel at Benefits Canada’s 2019 Face to Face Drug Plan Management Forum on Dec. 3 in Toronto.
In particular, Sotirakos highlighted that not harnessing this data is a missed opportunity from a result and risk-share model perspective. “We need to overcome our access barriers and tap into that evidence so we can create new models for novel therapies.”
